This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
https://awmsg.nhs.wales/
.
Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
crizotinib (Xalkori®)
Reference No. 3207
Publication date:
04/01/2017
Appraisal information
crizotinib (Xalkori®) 200 mg hard capsule
crizotinib (Xalkori®) 250 mg hard capsule
Company:
Pfizer Ltd
BNF category:
Malignant disease and immunosupression
NMG meeting date:
Not scheduled
AWMSG meeting date:
Not scheduled
Submission Type:
Nonsubmission
Status:
Not endorsed
Advice No:
Not available
Ratification by Welsh Government:
22/12/2016
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
In the absence of a submission from the holder of the marketing authorisation, crizotinib (Xalkori®) cannot be endorsed for use within NHS Wales for the treatment of adults with ROS1-positive advanced non-small cell lung cancer.
Statement of Advice (SOA)
Download
crizotinib (Xalkori) 3207 SOA
